News

US CDC Official in Charge of COVID, RSV Data Resigns Ahead of Vaccine Meeting
The scientist, Dr. Fiona Havers, told colleagues at the Centers for Disease Control and Prevention on Monday that she no ...
Northwest Asian Weekly2h
Dr. Helen Chu: CDC vaccine panel purge threatens public health
A leading infectious disease expert and one of the nation’s foremost COVID-19 researchers has voiced deep concerns about the ...
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...
STAT5d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
Clinical Advisor1d
RSV Vaccine mResvia Approved for Adults Aged 18 to 59 at Increased Risk
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
Kennedy's picks for vaccine advisory panel raise concerns about anti-vaccine bias
A few of the new members Health Secretary Robert F. Kennedy Jr. appointed to the federal panel have promoted misinformation about vaccines and public health.
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
The Manila Times1d
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- ...